Lachlan Brown
Stock Analyst at William Blair
(2.29)
# 2,737
Out of 5,014 analysts
10
Total ratings
50%
Success rate
11.99%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $197.32 | +1.36% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $37.48 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $4.45 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $11.79 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $438.92 | +36.70% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $327.00 | +7.03% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $25.12 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $95.45 | -5.71% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $106.86 | +105.89% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $197.32
Upside: +1.36%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $37.48
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $4.45
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.79
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $438.92
Upside: +36.70%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $327.00
Upside: +7.03%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $25.12
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $95.45
Upside: -5.71%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $106.86
Upside: +105.89%